MorphoSys Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Martinsried Germany (1992)

Organization Overview

First Clinical Trial
2009
NCT01023256
First Marketed Drug
2020
tafasitamab (Monjuvi)
First NDA Approval
2020
tafasitamab (Monjuvi)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Morphosys | MorphoSys AG | MorphoSys US Inc. | MORPHOSYS US INC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Dermatitis (Phase 1)

Dermatitis, Atopic (Phase 1)

Glomerulonephritis (Phase 2)

Glomerulonephritis, Membranous (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Prolymphocytic (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Non-Hodgkin (Phase 2)

Multiple Myeloma (Phase 2)

Multiple Sclerosis (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Prostatic Neoplasms (Phase 1)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 34
  • # of Trial APIs: 29